An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)-Reference-Cited by-同舟云学术

An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)

Published:2023-01-15 Issue:2 Volume:207 Page:138-149
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Gaughan Erin E.¹²^ORCID,Quinn Tom M.¹²,Mills Andrew³,Bruce Annya M.¹,Antonelli Jean¹,MacKinnon Alison C.⁴,Aslanis Vassilios⁴,Li Feng¹,O’Connor Richard¹,Boz Cecilia¹,Mills Ross¹,Emanuel Philip¹,Burgess Matthew¹,Rinaldi Giulia¹,Valanciute Asta¹,Mills Bethany¹,Scholefield Emma¹,Hardisty Gareth¹,Findlay Emily Gwyer¹,Parker Richard A.⁵,Norrie John⁵,Dear James W.⁶,Akram Ahsan R.¹²,Koch Oliver¹⁷,Templeton Kate⁸,Dockrell David H.¹⁷,Walsh Timothy S.¹⁹,Partridge Stephen⁴,Humphries Duncan⁴,Wang-Jairaj Jie⁴,Slack Robert J.⁴,Schambye Hans⁴,Phung De⁴,Gravelle Lise⁴,Lindmark Bertil⁴,Shankar-Hari Manu¹⁹^ORCID,Hirani Nikhil¹²,Sethi Tariq⁴,Dhaliwal Kevin¹²

Affiliation:

1. Centre for Inflammation Research, Edinburgh BioQuarter,

2. Department of Respiratory Medicine,

3. Exploristics, Belfast, United Kingdom;

4. Galecto Inc., Copenhagen, Denmark; and

5. Edinburgh Clinical Trials Unit, Usher Institute, and

6. Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom;

7. Infectious Diseases Department, Western General Hospital, Edinburgh, United Kingdom

8. Department of Medical Microbiology, and

9. Department of Critical Care, New Royal Infirmary of Edinburgh, Edinburgh BioQuarter, Edinburgh, United Kingdom;

Funder

LifeArc